Previous Section Index Home Page

11 Dec 2007 : Column 524W—continued

Mental Health: Employment

Mr. Harper: To ask the Secretary of State for Health pursuant to the written ministerial statement of 27 November 2007, on mental health and employment: meeting the challenge, when he expects to establish a mental health forum. [169958]

Mrs. McGuire: I have been asked to reply.

On 27 November we announced our intention to establish a mental health forum to bring together all those involved in the delivery of Pathways to Work support, in order to share evidence and experiences in relation to support for people with mental health conditions. When the rollout of Pathways to Work is completed, we will bring forward proposals for this forum.

Mentally Ill: Drugs

Mr. Laws: To ask the Secretary of State for Health how many people were prescribed drugs for (a) depression, (b) behaviour control/management and (c) mental health problems in each year since 1980-81; at what total cost in each year; and if he will make a statement. [172093]

Mr. Ivan Lewis: Not all prescriptions for drugs which are licensed for treating mental illness will have been prescribed for a mental illness. Some drugs, which are indicated for treating mental illness, are also prescribed for other illnesses such as narcolepsy and obstructive sleep apnoea syndrome. Some drugs used to treat depression are also used for other purposes.

Information on the total number of patients receiving prescriptions for medicines licensed for treating depression, behaviour control and other mental health problems from the national health service in England is not collected centrally.

Data are available on the total number of prescriptions dispensed in primary care for medicines licensed for treating these conditions, in each financial year from 1991-92 to 2006-07, and is shown in table 1. Prescriptions for behaviour control or management have been identified as those medicines which are indicated as central nervous system stimulants and drugs which are licensed for treating attention deficit hyperactivity disorder. Data on the number of prescriptions dispensed prior to 1991 are not reliable and have not been included in the table.


11 Dec 2007 : Column 525W
Table 1: Total number of prescriptions dispensed in primary care settings by the NHS in England for medicines which are licensed for treating (a) depression, (b) behaviour control or management and (c) other mental health problems between 1991-92 and 2006-07—data are for all ages, male and female combined
Thousand
Financial year All antidepressant drugs All central nervous system stimulants and drugs used for attention deficit hyperactivity disorder All drugs used in psychoses and related disorders

1991-92

9,167.3

69.9

3,605.4

1992-93

10,155.9

78.3

3,843.9

1993-94

10,999.3

89.6

4,095.7

1994-95

12,171.9

100.7

4,345.9

1995-96

13,617.7

120.0

4,615.6

1996-97

15,325.2

166.7

4,859.4

1997-98

17,285.1

200.4

5,164.0

1998-99

18,843.8

231.8

5,463.2

1999-2000

20,560.6

260.8

5,677.9

2000-01

22,633.7

272.0

5,857.1

2001-02

24,787.1

295.8

5,679.7

2002-03

26,675.4

353.1

6,068.9

2003-04

28,098.9

414.1

6,486.0

2004-05

28,913.4

470.5

6,600.1

2005-06

29,878.5

536.8

6,974.3

2006-07

31,704.6

630.8

7,367.1

Source:
Prescription Cost Analysis, NHS Information Centre for health and social care.

An indication of the total annual cost of these drugs can be obtained from data on their total net ingredient cost for each year. Data for 1980 to 1990 are shown in table 2 and data for 1991-92 to 2006-07 are shown in table 3. Data up to December 1990 were collected on a calendar year basis and data since 1991 have been collected on a financial year basis.

Table 2: Total net ingredient cost of prescriptions dispensed in primary care settings by the NHS in England for medicines which are licensed for treating (a) depression, (b) behaviour control or management and (c) other mental health problems 1980-90—data are for all ages, male and female combined
£000
All antidepressant drugs All drugs used in psychoses and related disorders All central nervous system stimulants and drugs used for attention deficit hyperactivity disorder

1980

18,513.2

4,897.9

79.1

1981

21,517.2

5,196.3

93.3

1982

24,087.7

6,242.0

123.3

1983

25,294.9

6,958.8

94.4

1984

25,373.9

7,407.3

80.4

1985

25,981.7

8,371.8

95.8

1986

27,334.8

8,450.7

86.5

1987

30,084.4

9,406.0

76.9

1988

31,992.7

10,640.0

60.5

1989

35,358.7

12,030.0

57.0

1990

40,867.9

12,835.2

56.7

Source:
Prescription Cost Analysis, NHS Information Centre for health and social care.

11 Dec 2007 : Column 526W

Table 3: Total net ingredient cost of prescriptions dispensed in primary care settings by the NHS in England for medicines which are licensed for treating (a) depression, (b) behaviour control or management and (c) other mental health problems 1991-92 to 2006-07—data are for all ages, male and female combined
£000
Financial year All antidepressant drugs All drugs used in psychoses and related disorders All central nervous system stimulants and drugs used for attention deficit hyperactivity disorder

1991-92

59,473.7

15,451.3

64.9

1992-93

88,427.2

16,870.0

124.4

1993-94

101,303.8

19,300.5

237.7

1994-95

123,959.8

22,384.8

326.1

1995-96

156,957.5

26,638.6

694.8

1996-97

201,867.6

32,946.5

1,345.1

1997-98

250,528.6

46,734.9

2,223.5

1998-99

287,968.7

65,508.7

3,373.4

1999-2000

322,485.3

86,077.5

4,487.2

2000-01

309,081.2

106,785.0

5,404.8

2001-02

353,078.7

140,698.1

6,641.7

2002-03

385,655.9

173,590.2

10,440.5

2003-04

398,132.2

205,563.6

14,773.1

2004-05

393,588.2

218,429.7

19,837.4

2005-06

322,035.5

228,695.2

25,691.5

2006-07

285,623.6

251,855.6

30,387.9

Notes:
1. Prescription information is taken from the PCA system, supplied by the Prescription Pricing Division of the Business Services Authority. It is based on a full analysis of all prescriptions dispensed in the community by community pharmacists and appliance contractors, dispensing doctors, and prescriptions submitted by prescribing doctors for items personally administered in England.
2. The data include prescriptions written in Wales, Scotland, Northern Ireland and the Isle of Man, but dispensed in England. The data apply to primary care settings and exclude drugs dispensed in hospitals, including mental health trusts, or private prescriptions.
3. The net ingredient cost is the basic cost of a drug. They do not take account of discounts, dispensing costs, fees or prescription charges income.
4. The data up to 1990 are not consistent with data from 1991 onwards. Figures for 1980-90 are based on fees, and on a sample of one in 200 prescriptions dispensed by community pharmacists and appliance contractors only. Figures for 1991 onwards are based on items and cover all prescriptions dispensed by community pharmacists, appliance contractors dispensing doctors and prescriptions submitted by prescribing doctors for items personally administered.
Source:
Prescription Cost Analysis (PCA), NHS Information Centre for health and social care.

NHS

Mr. Oaten: To ask the Secretary of State for Health what plans he has to break up the commercial directorate of the NHS and create regional centres to carry out its work; and if he will make a statement. [173415]

Mr. Bradshaw: The Commercial Directorate will continue to play a major role in providing commercial expertise to the Department and in helping build commercial capability across the national health service. It will exercise its role in partnership with strategic health authorities and other NHS organisations.

NHS: British Nationality

Mike Penning: To ask the Secretary of State for Health whether any jobs within the NHS are reserved for British citizens; and if he will make a statement. [170973]

Ann Keen: When recruiting, national health service employers will follow employment laws, the immigration
11 Dec 2007 : Column 527W
rules and European Community directives and should be mindful of any guidance on employment published by the Department and its agencies. These documents will include provisions on the consideration and employment of applicants in relation to their nationality, ethnicity, race and immigration status.


Next Section Index Home Page